| 000 | 01632 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518042852.0 | ||
| 264 | 0 | _c20200227 | |
| 008 | 202002s 0 0 eng d | ||
| 022 | _a1573-2584 | ||
| 024 | 7 |
_a10.1007/s11255-019-02180-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMasuda, Takahiro | |
| 245 | 0 | 0 |
_aImpact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients. _h[electronic resource] |
| 260 |
_bInternational urology and nephrology _cSep 2019 |
||
| 300 |
_a1623-1629 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aBody Fluids _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoalbuminemia _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRenal Insufficiency, Chronic _xcomplications |
| 650 | 0 | 4 |
_aSerum Albumin _xanalysis |
| 650 | 0 | 4 |
_aTolvaptan _xpharmacology |
| 700 | 1 | _aOhara, Ken | |
| 700 | 1 | _aNagayama, Izumi | |
| 700 | 1 | _aMatsuoka, Ryo | |
| 700 | 1 | _aMurakami, Takuya | |
| 700 | 1 | _aNakagawa, Saki | |
| 700 | 1 | _aOka, Kentanro | |
| 700 | 1 | _aAsakura, Maki | |
| 700 | 1 | _aIgarashi, Yusuke | |
| 700 | 1 | _aFukaya, Yukimura | |
| 700 | 1 | _aMiyazawa, Yasuharu | |
| 700 | 1 | _aMaeshima, Akito | |
| 700 | 1 | _aAkimoto, Tetsu | |
| 700 | 1 | _aSaito, Osamu | |
| 700 | 1 | _aNagata, Daisuke | |
| 773 | 0 |
_tInternational urology and nephrology _gvol. 51 _gno. 9 _gp. 1623-1629 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s11255-019-02180-8 _zAvailable from publisher's website |
| 999 |
_c29761663 _d29761663 |
||